Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma

Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma—a meta-analysis

Published:2018-12 Issue: Volume:105 Page:1-9
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

McNamara Mairéad Geraldine^ORCID,Slagter Astrid E.,Nuttall Christina,Frizziero Melissa,Pihlak Rille,Lamarca Angela,Tariq Noor,Valle Juan W.^ORCID,Hubner Richard A.,Knox Jennifer J.,Amir Eitan

Funder

Collins PhD fellowship

Pancreatic Cancer UK

European Society for Medical Oncology

Pancreatic Cancer Research Fund

Timpson PhD fellowship

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference51 articles.

1. Sorafenib blocks the RAF/MEK/ERK pathwat, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5;Liu;Cancer Res,2006

2. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

3. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial;Cheng;Lancet Oncol,2009

4. Management of hepatocellular carcinoma: an update;Bruix;Hepatology,2011

5. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma;Peck-Radosavljevic;Eur J Gastroenterol Hepatol,2010

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care;Digestive and Liver Disease;2024-09

2. Patients with uHCC and Child-Pugh B8/9 also benefit from a combination of antiangiogenic agents and PD-1 inhibitors: a multicenter real-world study;2024-06-10

3. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update;Journal of Clinical Oncology;2024-05-20

4. Hepatocellular carcinoma: Advances in systemic therapies;F1000Research;2024-05-07

5. Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives;Cancers;2024-03-31